Issue 24 | 2016
Get instant access to latest e-book

latest news


Jul 2016

Apricus Biosciences Expands Existing Vitaros® Partnership with Ferring Pharmaceuticals

Apricus Biosciences Inc a biopharmaceutical company advancing innovative medicines in urology and rheumatology today announced that it has further expanded its exclusive distribution agreement with Ferring Pharmaceuticals Ferring for the commercialization of Vitaros Apricus novel topical o..


Jul 2016

Germany plans to extend price brake for drugs under statutory insurance

Germany wants to extend a price brake for drugs covered by statutory health insurance for five years beyond stretching out the measure introduced in a draft law seen by Reuters shows The health ministry estimates savings from the extension will amount to between and billion euros billion ministry sources said Under the draft law the governme..


Jul 2016

Kite Pharma Licenses Enabling Technology for the Development of Off-the-Shelf Allogeneic T-Cell Therapies

Kite Pharma Inc a clinicalstage biopharmaceutical company focused on developing engineered autologous Tcell therapy eACT products for the treatment of cancer today announced that it has entered into an exclusive worldwide license agreement with The Regents of the University of California on behalf of the University of ..


Jul 2016

Celgene drug fails to extend survival in lymphoma study

Celgene Corp said on Monday that its flagship drug Revlimid failed to extend survival as a maintenance therapy for a type of blood cancer after patients had responded to prior treatment As a result the US biotechnology company said it would not seek an additional approval for Revlimid for that use and its shares fell ..

events

25 - 27

Jul 2016

3rd Annual Advanced API Convention

UBM India
The Westin Mumbai Garden City


Jul 2016

Organovo to Begin Trading on Nasdaq Stock Market



Jul 2016


Jul 2016


knowledge bank

  • interviews

    Datwyler Pharma Packaging

    Senior Manager Global Scientific Affairs
    Renaud Janssen, Ph.D. is the Senior Manager of Global Scientific Affairs at Datwyler Pharma Packaging. He frequently presents on international conferences on subjects related to elastomeric and aluminium/plastic closures for pharm..

  • Articles

    When Orphan Drugs Make All the Difference

    Orphan drugs those medications that are typically produced in small quantities for limited patient populations are growing in importance worldwide Once largely considered too costly to produce given the limited number of patients affected by a particular disease new technology and new breakthroughs in biopharma have changed the landscape allowing more orphan drugs to be produced than ever before t..

  • Research Insights

    Critical parameters in targeted drug development: the pharmacological audit trail

    Abstract The Pharmacological Audit Trail PhAT comprises a set of critical questions that need to be asked during discovery and development of an anticancer drug Key aspects include defining a patient population establishing pharmacokinetic characteristics providing evidence of target engagement pathway modulation and biological effect with proof of concept pharmacodynamic biomarkers determining intermediate biomarkers of response assessing ..

editorial Section

  • Competing on Alignment

    SWOT is both the most powerful and least understood strategic management tool Used correctly it translates the outputs of many other market analyses into a small number of key issues..

  • Future Trends in Ion Channel and Solute Transporter Drug Discovery

    Gene family members of the ion channel and solute transporter SLC families represent both historical targets of pharmaceutical significance and serve as exciting opportunities for current and future therapeutic development The common property of ion movement for many of the SLCs lends itself to considering platforms used in ion channel research to enable early drug discovery In addition the convergence of advances in both genetic analysis and assay technology bodes well for the identification of the next generation of ion channel and transporterbased drugs in the near future..

  • Issues & Concerns in Conducting Clinical Trials in India

    Issues like approval delays deficiencies of functioning of CROs and other stake holders liabilities and compensation to injured subjects insurance issues etc still remain in India which has made multinational companies to rethink on opting for India to conduct clinical trials in India recently There is a need for a law to ensure that the people who undergo clinical trials are not exploited and should be well informed about risk as well to provide..

  • Innovation Challenges in Manufacturing

    Most firms in the pharmaceutical industry think globally to expand demand for their products There are amenities from which firms leverage to launch a strategy to gain global market share These amenities include the regulatory dimension which helps reassign resources within and outside the firm..

  • Quality by Design

    The article presents a novel approach to applying Quality by Design QbD principles to the development of analytical methods Common critical parameters in HPLC gradient time temperature pH of the aqueous eluent and stationary phase are evaluated within the Quality by Design framework It is useful for the robust analytical method development and Design Space optimisation..

  • Peptides Remain a Growth Story

    Cloud solutions offer immediate returns in improving operational performance and reducing costs Multiple approaches to cloud solutions will be needed to satisfy life science industry needs complicating the development of a coherent cloud strategy..